| Literature DB >> 27920809 |
Giovanni Iolascon1, Francesca Gimigliano2, Antimo Moretti1, Ilaria Riccio1, Massimo Di Gennaro3, Maddalena Illario4, Valeria Marina Monetti5, Valentina Orlando5, Enrica Menditto5.
Abstract
Subjects with chronic diseases are more likely to be nonpersistent to pharmacological treatment. Lack of persistence is common among subjects using oral anti-osteoporotic drugs, and leads to increased risk of fragility fracture. The aim of our retrospective study is to analyze the rates and reasons for discontinuation of anti-osteoporotic drugs in the Campania Region. Subjects aged over 40 years were included if they had received at least one prescription for any anti-osteoporotic drugs. Data were obtained from an administrative database of regional data on outpatient drug prescriptions reimbursed by the National Health Service. Patients were followed until the discontinuation of anti-osteoporotic therapy or until the end of the observation period. A total of 30,048 were incident users of anti-osteoporotic drugs: 28,317 (94.2%) females. The mean age of the cohort was 69.0±10.0 years. Weekly bis-phosphonates (51.1%) were the most commonly prescribed drugs. In the overall population, persistence rates were 34.8% after 6 months and 13.4% at one year. A multivariate Cox proportional hazard analysis showed that daily regimen (HR 1.9) treatments remained at higher risk of early discontinuation compared to weekly regimen therapies. Our data showed that the persistence to osteoporosis therapy is significantly worse than reported in literature.Entities:
Keywords: anti-osteoporotic drugs; bi-sphosphonates; database; osteoporosis; persistence
Year: 2016 PMID: 27920809 PMCID: PMC5119710 DOI: 10.11138/ccmbm/2016.13.2.127
Source DB: PubMed Journal: Clin Cases Miner Bone Metab ISSN: 1724-8914